A Phase I Trial of Intravenous CG7870, a Replication-Selective, Prostate-Specific Antigen–Targeted Oncolytic Adenovirus, for the Treatment of Hormone-Refractory, Metastatic Prostate Cancer

This publication has 28 references indexed in Scilit:

• Ablating CAR and Integrin Binding in Adenovirus Vectors Reduces Nontarget Organ Transduction and Permits Sustained Bloodstream Persistence Following Intraperitoneal Administration
  Molecular Therapy, 2004
• TNFerade Biologic, an Adenovector With a Radiation-Inducible Promoter, Carrying the Human Tumor Necrosis Factor Alpha Gene: A Phase I Study in Patients With Solid Tumors
  Journal of Clinical Oncology, 2004
• Prostate cancer update
  Current Opinion in Oncology, 2003
• Phase II Trial of Intravenous CI-1042 in Patients With Metastatic Colorectal Cancer
  Journal of Clinical Oncology, 2003
• Intravascular adenoviral agents in cancer patients: Lessons from clinical trials
  Cancer Gene Therapy, 2002
• Phase I Trial of Intraperitoneal Injection of the E1B-55-kd-Gene-Deleted Adenovirus ONYX-015 (dl1520) Given on Days 1 Through 5 Every 3 Weeks in Patients With Recurrent/Refractory Epithelial Ovarian Cancer
  Journal of Clinical Oncology, 2002
• Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity
  Gene Therapy, 2001
• Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer
  Oncogene, 2000
• Pre-Existent Adenovirus Antibody Inhibits Systemic Toxicity and Antitumor Activity of CN706 in the Nude Mouse LNCaP Xenograft Model: Implications and Proposals for Human Therapy
  Human Gene Therapy, 2000
• Cytokines in adenoviral disease in children: Association of interleukin-6, interleukin-8, and tumor necrosis factor alpha levels with clinical outcome
  The Journal of Pediatrics, 1994